Oxford BioMedicaOXBDF 71 Receivables Turnover is 3.86 as of Dec. 2025. GuruFocus rates OXBDF with a GF Score™ of 71/100 and a GF Value™ of $6.62 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 843 Biotechnology companies, Oxford BioMedica ranks better than 65.24% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Oxford BioMedica's Revenue for the
six
months ended in Dec. 2025 was $127.9 Mil. Oxford BioMedica's average Accounts Receivable for the
six
months ended in Dec. 2025 was $33.1 Mil.
Hence, Oxford BioMedica's Receivables Turnover for the
six
months ended in Dec. 2025 was 3.86.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Oxford BioMedica Receivables Turnover Related Terms
Oxford BioMedica Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Oxford BioMedica's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OXBDF vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Oxford BioMedica's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxford BioMedica Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oxford BioMedica's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Oxford BioMedica's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxford BioMedica (OXBDF) has a Receivables Turnover of 3.86 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Oxford BioMedica and its competitors. According to the industry distribution chart, Oxford BioMedica ranks #293 out of 843 companies in the Biotechnology industry, placing it in the top 34.8%.
Is Oxford BioMedica's Receivables Turnover too high?
Oxford BioMedica's current Receivables Turnover is 3.86. The Biotechnology industry median Receivables Turnover is 5.28. Oxford BioMedica's value of 3.86 is 26.9% below this industry median. Based on the distribution chart, Oxford BioMedica ranks #293 out of 843 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Oxford BioMedica has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oxford BioMedica ranks #293 out of 843 companies for Receivables Turnover. This puts Oxford BioMedica in the upper half of its industry. The industry median Receivables Turnover is 5.28. Oxford BioMedica's value of 3.86 is 26.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 843 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oxford BioMedica's current Receivables Turnover of 3.86 is 26.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Oxford BioMedica and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oxford BioMedica's current Receivables Turnover is 3.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (OXBDF) is currently considered Modestly Overvalued. The stock's GF Value™ is $6.62, compared to a current price of $7.93 — trading 19.7% above its estimated fair value. The current Receivables Turnover is 3.86 and 26.9% below the Biotechnology industry median of 5.28. Oxford BioMedica's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Oxford BioMedica (OXBDF), the current Receivables Turnover is 3.86 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oxford BioMedica (OXBDF) Overvalued in 2026?
Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued.
The current stock price of $7.93 is trading 19.7% above its estimated GF Value™ of $6.62.
GuruFocus considers Oxford BioMedica to be Modestly Overvalued.
Key valuation signals for OXBDF:
Receivables Turnover: 3.86
GF Value™: $6.62 vs. price of $7.93 (19.7% above fair value)
Industry Position: 26.9% below the Biotechnology median (#293 of 843)
No single metric tells the full story. See the OXBDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
71GF Score
Get the complete analysis for OXBDF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OXBDF has been successfully added to your 
